Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Genesis Health International Inc. dba Genesis
WARNING LETTER
•Genesis Health International Inc. dba Genesis•December 31, 2025

Genesis Health International Inc. dba Genesis – FDA Warning Letter, Dec 31, 2025

Record Details

The FDA issued a Warning Letter to Genesis Health International Inc. dba Genesis on February 20, 2026, following a December 2025 review of their website, trygenesis.com. The letter identified significant violations related to the marketing of compounded semaglutide and tirzepatide drug products. The primary issues involve misbranding under the Federal Food, Drug, and Cosmetic Act (FDCA). Genesis's website falsely implied the company was the compounder of these drugs, and made deceptive claims such as "Contains the same active ingredient as Ozempic® and Wegovy®" and "Same active ingredient as Mounjaro®." These statements falsely suggested the compounded products were FDA-approved or had undergone similar safety and effectiveness evaluations, which they have not. These actions constitute misbranding under FDCA sections 502(a) and 502(bb), with their introduction into interstate commerce violating section 301(a). The FDA mandates immediate corrective action. Within fifteen working days, Genesis must provide a written response detailing steps taken to address these violations and prevent recurrence, including identifying actual product compounders, providing sample labeling, and either removing or modifying all false or misleading website claims. Failure to comply could lead to legal action, including product seizure and injunction.

Company
Genesis Health International Inc. dba Genesis
Inspection date
December 31, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Matthew J. Lash (Acting Director)
View Company Profile

ID · 4a6b3412-54f9-408e-bb1f-e19bc98ac3ff

Violation Codes10
FD&C Act 502(a)FD&C Act 502(b)21 U.S.C. 352(a)21 U.S.C. 352(bb)FD&C Act 301(a)21.U.S.C. 331(a)FD&C Act 301(c)21 U.S.C. 331(c)FD&C Act 503AFD&C Act 503B

Full citation text and observation details available on the Dashboard.

Other documents for Genesis Health International Inc. dba Genesis
  • WARNING_LETTER - 2026-03-01March 1, 2026

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Genesis Health International Inc. dba Genesis
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.